Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF1JO7
|
|||
| Drug Name |
CXA10
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Focal segmental glomerulosclerosis [ICD-11: MF8Y] | Phase 2 | [1] | |
| Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 2 | [2] | ||
| Company |
Complexa
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Inactivator | [3] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [3] | |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03422510) FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04053543) CXA-10 Study in Subjects With Pulmonary Arterial Hypertension. U.S. National Institutes of Health. | |||
| REF 3 | The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.